NASDAQ · SPRY
Healthcare · Biotechnology
$5.65
Down-$0.45 (-7.38%)
Updated Aug 16, 2026, 2:57 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SPRY closed at $5.65 after 20 trading sessions, down 12.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $5.10 | $5.84 | $5.00 | $5.65 | 5.05M |
| Aug 13, 2026 | $6.08 | $6.19 | $5.90 | $6.10 | 1.98M |
| Aug 12, 2026 | $5.96 | $6.075 | $5.8101 | $6.05 | 1.31M |
| Aug 11, 2026 | $5.98 | $5.98 | $5.80 | $5.95 | 1.35M |
| Aug 10, 2026 | $6.06 | $6.1846 | $5.80 | $5.91 | 1.33M |
| Aug 7, 2026 | $5.60 | $6.16 | $5.575 | $6.16 | 2.16M |
| Aug 6, 2026 | $5.38 | $5.60 | $5.38 | $5.55 | 1.26M |
| Aug 5, 2026 | $5.32 | $5.46 | $5.2198 | $5.36 | 2.54M |
| Aug 4, 2026 | $5.50 | $5.50 | $5.23 | $5.32 | 1.93M |
| Aug 3, 2026 | $5.08 | $5.485 | $4.9102 | $5.46 | 2.14M |
| Jul 31, 2026 | $5.55 | $5.605 | $5.11 | $5.13 | 2.08M |
| Jul 30, 2026 | $5.80 | $5.8525 | $5.48 | $5.63 | 1.63M |
| Jul 29, 2026 | $5.60 | $5.85 | $5.3499 | $5.83 | 6.44M |
| Jul 28, 2026 | $5.72 | $6.01 | $5.66 | $5.67 | 1.35M |
| Jul 27, 2026 | $6.00 | $6.06 | $5.62 | $5.76 | 1.82M |
| Jul 24, 2026 | $6.00 | $6.22 | $5.76 | $5.94 | 3.48M |
| Jul 23, 2026 | $6.10 | $6.10 | $5.765 | $6.00 | 2.66M |
| Jul 22, 2026 | $6.40 | $6.6199 | $6.06 | $6.06 | 3.12M |
| Jul 21, 2026 | $6.40 | $6.49 | $6.155 | $6.36 | 4.88M |
| Jul 20, 2026 | $7.00 | $7.1407 | $6.42 | $6.44 | 2.93M |
The latest Smart Investors Daily articles mentioning SPRY.
SPRY research
Company profile and research snapshot.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 25, 2026 | Leerink Partners | Outperform | — |
| May 28, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 4, 2025 | Roth Capital | Buy | — |
| Mar 7, 2025 | Scotiabank | Sector Outperform | — |
| Jan 14, 2025 | Raymond James | Strong Buy | — |
No generated briefing is available yet.
Yahoo · Jul 15, 2026
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple. On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company’s Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company’s current President, has […]
Benzinga · Jul 9, 2026
ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
Yahoo · Jul 8, 2026
CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo · Jul 7, 2026
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a CEO succession, in which c
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRY.
